Skip to content

Journal · Cancer metastasis · Updated 22 November 2026

Clinical & Experimental Metastasis

Read Clinical & Experimental Metastasis articles on DeepDyve. No university library needed.

Clinical & Experimental Metastasis covers how cancer spreads and how metastases are treated, with recent papers on radiosurgery for brain metastases, tumor-derived extracellular vesicles, prostate cancer in bone and the motor protein KIF14. Springer Nature publishes it, and it has published since 1983. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Clinical & Experimental Metastasis
Journal cover

Clinical & Experimental Metastasis at a glance

Full title
Clinical & Experimental Metastasis
Abbreviation (NLM)
Clin Exp Metastasis
Publisher
Springer Nature
Print ISSN
0262-0898
Online ISSN (eISSN)
1573-7276
First published
1983
Subjects
Neoplasms
Access model
Hybrid (35% free to read in 2026)

Ways to access Clinical & Experimental Metastasis

35% of the articles Clinical & Experimental Metastasis published from January 1 to November 20, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 35% of Clinical & Experimental Metastasis articles published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Clinical & Experimental Metastasis. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Clinical & Experimental Metastasis articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Clinical & Experimental Metastasis’ 2025 Journal Impact Factor is 3.7, and its 5-year Impact Factor is 3.7.

3.7

Journal Impact Factor (2025)

3.7

5-year Impact Factor (2025)

6 days

Median time to first decision

Source: journal metrics on the Clinical & Experimental Metastasis homepage (Springer Nature), checked November 22, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Clinical & Experimental Metastasis research worth reading

Published January to May 2026. Summaries describe what the authors report.

  1. LitStreamBrain metastases · Radiosurgery

    Gamma knife radiosurgery for cerebellar brain metastases: clinical outcomes and artificial intelligence-based predictive modeling

    In 490 patients with 1296 cerebellar metastases treated with Gamma Knife radiosurgery, the authors report local control of 82.5% and median survival of 10.2 months, better with immunotherapy, and a neural network that predicted outcomes well.

    Reyes et al. · Clinical & Experimental Metastasis, published online February 4, 2026 · DOI 10.1007/s10585-026-10394-1

  2. LitStreamLung cancer · Brain metastases

    Local control and dose selection for lung cancer brain metastases treated with radiosurgery: an artificial intelligence model

    Using lung cancer brain metastases treated with Gamma Knife radiosurgery at one center from 2014 to 2024, the authors trained a model that predicted local control well (C-index 0.83) and could recommend an individualized prescription dose.

    Reyes et al. · Clinical & Experimental Metastasis, published online May 26, 2026 · DOI 10.1007/s10585-026-10409-x

  3. LitStreamCancer biology · Biomarkers

    KIF14 in cancer biology: implications for diagnosis and therapy

    The authors review how the motor protein KIF14, overexpressed in breast, ovarian, lung, liver and brain tumors and linked to poor outcomes and therapy resistance, drives cancer progression, and weigh its promise as a prognostic biomarker and therapeutic target.

    Bishoyi et al. · Clinical & Experimental Metastasis, published online January 9, 2026 · DOI 10.1007/s10585-025-10389-4

  4. Open accessExtracellular vesicles · Pre-metastatic niche

    Contribution of tumor-derived extracellular vesicles in the establishment of the pre-metastatic niche: lessons learned from past experimentations and future directions

    Reviewing 120 papers on in vivo experiments, the authors identify seven ways tumor-derived extracellular vesicles prepare distant sites for metastasis, from immune reprogramming to bone remodeling, creating an inflammatory and immunosuppressive environment that favors tumor growth.

    Blavier et al. · Clinical & Experimental Metastasis, published online March 7, 2026 · DOI 10.1007/s10585-026-10396-z

  5. LitStreamProstate cancer · Bone metastasis

    Matrix and stromal cues cooperatively regulate dormancy-like states of prostate cancer in a dual-niche metastatic model

    With an engineered model of primary tumor and bone environments, the authors report that bone matrix–derived factors slowed prostate cancer growth and pushed cells toward dormancy, while primed bone marrow stromal cells drove tumor growth and spread.

    Han et al. · Clinical & Experimental Metastasis, published online May 16, 2026 · DOI 10.1007/s10585-026-10405-1

See every Clinical & Experimental Metastasis article on DeepDyve

Questions about Clinical & Experimental Metastasis

How can I read Clinical & Experimental Metastasis articles without a subscription?

35% of Clinical & Experimental Metastasis articles published from January 1 to November 20, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Clinical & Experimental Metastasis articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Clinical & Experimental Metastasis?

Clinical & Experimental Metastasis’ NLM (PubMed) abbreviation is Clin Exp Metastasis.

What is the ISSN of Clinical & Experimental Metastasis?

The print ISSN is 0262-0898 and the online ISSN is 1573-7276.

What is the impact factor of Clinical & Experimental Metastasis?

Clinical & Experimental Metastasis’ Journal Impact Factor is 3.7 (2025), and its 5-year Impact Factor is 3.7, according to Springer Nature’s published metrics.

Is Clinical & Experimental Metastasis open access?

Clinical & Experimental Metastasis is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 20, 2026, 21 of 60 Clinical & Experimental Metastasis articles (35%) carry a Creative Commons license, per Crossref.

Clinical & Experimental Metastasis articles on DeepDyve are licensed from Springer Nature. Journal facts as of 22 November 2026.

Start reading Clinical & Experimental Metastasis today

One month free, then less than $2 a day. Clinical & Experimental Metastasis, plus millions of articles from thousands of journals.

Start free month

Like this: